STING Agonists: A new tool in the fight against Bladder Cancer

With the bladder cancer market projected to grow in the upcoming years, the development of new immunotherapies like STING Agonists allow for a breakthrough in the fight against bladder cancer. Written by Omar Aly, Sarah Bortel, Jakob Heinz, and Andrés Melendez.

Bladder Cancer Overview

Bladder cancer is the most expensive cancer per the National Cancer Institute, being ranked first in lifetime treatment costs and is the sixth most frequently diagnosed cancer. Estimates indicate that by the year 2023, the United States bladder cancer market will be close to six billion dollars. In 2018, Datamonitor Healthcare estimated 546,400 incident cases of bladder cancer globally, predicting 605,300 incident cases by 2027 as well. Future growth of this market can be attributed to several key factors: the availability of novel drugs and strong distribution pipeline, the organization of lifestyle and increasing public awareness, and the rise in bladder cancer incidence due to an aging population.

The story behind STING Agonist

10 years ago, Glen Barber was studying the immune system response to pathogens at the University of Miami when he discovered STING. He found that cells missing the STING protein were vulnerable to viral infections. Glen and his laboratory were able to discover the innate immune senator STING and STING controlled cytosolic DNA innate immune signaling pathway.

APPENDIX

Key Industry Players
Due to the growing bladder cancer market, many key companies have emerged as dominant figures. Several companies are based in the United States such as Merck & Co, Pfizer, and Bristol-Myers Squibb. Other international companies such as Roche (CH), AstraZeneca (UK), GlaxoSmithKline (UK), & Sanofi Pasteur (Fr) have also emerged as dominant players in the bladder cancer industry.

The newest student-run healthcare and life-sciences consulting group at the Johns Hopkins University